Search results
Your search for ���������������������������������������������:kn39��� returned no results
Showing 91 to 105 of 763 results for ���������������������������������������������:know���
Showing 91 to 105 of 763 results for ���������������������������������������������:know���
from mesh surgery on page 11 of this decision aid. It is not possible to know for sure what will happen to any individual woman 4 More...
NICE guidance on the benefits of implementing
retropubic mesh sling than after the other operations. It is not possible to know for sure what will happen to any individual woman 4...
information about the options. They cover the things most women may want to know about. On page 9 you can write down how you feel about...
Find out about the progress made by the health and care system in implementing NICE guidance on cardiovascular disease management
A quick guide for practitioners supporting people growing older with learning disabilities.
Burosumab for treating X-linked hypophosphataemia in children and young people (HST8)
Evidence-based recommendations on burosumab (Crysvita) for X-linked hypophosphataemia in children and young people.
Join Nice's Public Involvement Programme expert panel
NICE quick guide - moving between hospital and home, including care homes
Tell us about an interventional procedure you think should be assessed by NICE.
Abortion care. Patient decision aid on choosing between medical or surgical abortion before 14 weeks
information about the options. They cover the things most women may want to know about. On page 10 you can write down how you feel about...
do to reduce your risk of bowel and other cancers. It is not possible to know in advance what will happen to any one person. c NICE...
Unintentional injuries: prevention strategies for under 15s (PH29)
This guideline covers strategies, regulation, enforcement, surveillance and workforce development in relation to preventing unintentional injuries in the home, on the road and during outdoor play and leisure.
Pembrolizumab for adjuvant treatment of completely resected stage 3 melanoma (TA766)
Evidence-based recommendations on pembrolizumab (Keytruda) for adjuvant treatment of completely resected stage 3 melanoma in adults.
Evidence-based recommendations on voretigene neparvovec (Luxturna) for RPE65-mediated inherited retinal dystrophies in people with vision loss caused by inherited retinal dystrophy from confirmed biallelic RPE65 mutations and who have sufficient viable retinal cells.